Incytevs.Neurocrine Biosciences
INCY vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte is about 1.6× larger than Neurocrine Biosciences by market cap; Incyte trades at the lower P/E (14.0 vs 20.3); year to date, Incyte leads (+14.9% vs +1.2%).
Side by side
| INCY | NBIX | |
|---|---|---|
| Market cap | $22.5B | $14.3B |
| Price | $112.75 | $141.25 |
| Today | −0.6% | −1.5% |
| Return YTD | +14.9% | +1.2% |
| Return 1Y | +30.1% | +4.7% |
| Since June 26, 2026 | −0.9% | −16.2% |
| P/E | 14.0 | 20.3 |
| P/S | 3.9 | 4.3 |
| P/B | 3.5 | 3.9 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More INCY & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.